WO2003047494A3 - Reverse micelle compositions and uses thereof - Google Patents

Reverse micelle compositions and uses thereof Download PDF

Info

Publication number
WO2003047494A3
WO2003047494A3 PCT/US2002/038474 US0238474W WO03047494A3 WO 2003047494 A3 WO2003047494 A3 WO 2003047494A3 US 0238474 W US0238474 W US 0238474W WO 03047494 A3 WO03047494 A3 WO 03047494A3
Authority
WO
WIPO (PCT)
Prior art keywords
mucosal
reverse micelle
micelle compositions
hydrophilic
biologically active
Prior art date
Application number
PCT/US2002/038474
Other languages
French (fr)
Other versions
WO2003047494A2 (en
Inventor
Panos P Constantinides
Likan Liang
Eun-Hyun Jang
Original Assignee
Dor Biopharma Inc
Panos P Constantinides
Likan Liang
Eun-Hyun Jang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dor Biopharma Inc, Panos P Constantinides, Likan Liang, Eun-Hyun Jang filed Critical Dor Biopharma Inc
Priority to AU2002362040A priority Critical patent/AU2002362040A1/en
Publication of WO2003047494A2 publication Critical patent/WO2003047494A2/en
Publication of WO2003047494A3 publication Critical patent/WO2003047494A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0291—Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Abstract

The invention relates to reverse micelle compositions and method s for drug delivery suitable for promoting the transmucosal absorption of biologically active molecules, especially drugs with poor intrinsic bioavailability, such as peptides, proteins, vaccines, and nucleic acids. The delivery system of this invention preferably comprises fatty acid esters and their hydrophilic derivatives that associate with water and othe polar solvents to form stable reverse micelles. When administered as pharmaceutical to mucosal surfaces following oral or intrasanal administration, biologically active molecules principally solubilized in the hydrophilic phase are protected from digestion by mucosal enzymes and other mucosal degradative processes and are taken up by absorptive cell mechanisms and reach appropriate body compartments. The reverse micelle compositions described in this invention may comprise monoglycerides and/or their transesterified products containing C6-C12 fatty acids chains, wherein the transester groups consist of hydrophilic moieties.
PCT/US2002/038474 2001-12-03 2002-12-03 Reverse micelle compositions and uses thereof WO2003047494A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002362040A AU2002362040A1 (en) 2001-12-03 2002-12-03 Reverse micelle compositions and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US33647101P 2001-12-03 2001-12-03
US60/336,471 2001-12-03
US35472002P 2002-02-05 2002-02-05
US60/354,720 2002-02-05
US37767402P 2002-05-03 2002-05-03
US60/377,674 2002-05-03

Publications (2)

Publication Number Publication Date
WO2003047494A2 WO2003047494A2 (en) 2003-06-12
WO2003047494A3 true WO2003047494A3 (en) 2003-09-25

Family

ID=27407121

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038474 WO2003047494A2 (en) 2001-12-03 2002-12-03 Reverse micelle compositions and uses thereof

Country Status (2)

Country Link
AU (1) AU2002362040A1 (en)
WO (1) WO2003047494A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2537029C (en) * 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds
CN102753150A (en) 2010-01-12 2012-10-24 诺沃—诺迪斯克有限公司 Pharmaceutical compositions for oral administration of insulin peptides
EP3214174B1 (en) 2010-03-04 2019-10-16 InteRNA Technologies B.V. A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
DE102010013064A1 (en) * 2010-03-26 2011-12-15 Gabriele Blume Novel carrier system for the transport of active ingredients into the skin
NZ704322A (en) 2010-07-06 2016-07-29 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
EP3369818B1 (en) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna for treating head and neck cancer
EP2917348A1 (en) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
EP2946788A1 (en) 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
KR101988240B1 (en) * 2017-02-27 2019-06-12 주식회사 디알나노 Methylene blue complex for treating skin disease and its use thereof
CN106983720A (en) * 2017-05-19 2017-07-28 浙江工业大学 A kind of reverse micelle includes the preparation method of insulin system
CA3079524A1 (en) 2017-11-03 2019-05-09 Interna Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
CN111012758B (en) * 2019-12-31 2021-10-15 浙江工业大学 Preparation method of nattokinase microcapsule

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292499A (en) * 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5451569A (en) * 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5646109A (en) * 1991-04-19 1997-07-08 Lds Technologies, Inc. Convertible microemulsion formulations
US6316497B1 (en) * 1998-06-24 2001-11-13 Abbott Laboratories Self-emulsifying systems containing anticancer medicament

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292499A (en) * 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5646109A (en) * 1991-04-19 1997-07-08 Lds Technologies, Inc. Convertible microemulsion formulations
US5451569A (en) * 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US6316497B1 (en) * 1998-06-24 2001-11-13 Abbott Laboratories Self-emulsifying systems containing anticancer medicament

Also Published As

Publication number Publication date
AU2002362040A1 (en) 2003-06-17
WO2003047494A2 (en) 2003-06-12
AU2002362040A8 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
HK1071054A1 (en) Stabilized reverse micelle compositions and uses thereof
Mahmood et al. SEDDS: A game changing approach for the oral administration of hydrophilic macromolecular drugs
WO2003047494A3 (en) Reverse micelle compositions and uses thereof
WO2008058547A3 (en) Alpha-lactalbumin composition
JP4195486B2 (en) Lactoferrin complex and method for producing the same
WO2002051390A3 (en) Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
WO2003099225A3 (en) Compositions for delivering nucleic acids to cells
ITMI20001173A1 (en) PROLONGED RELEASE PHARMACEUTICAL COMPOSITIONS FOR THE PARENTERAL ADMINISTRATION OF BIOLOGICALLY ACTIVE HYDROPHILE SUBSTANCES.
EP2471512A3 (en) Non-polar photosensitizer formulations for photodynamic therapy
JP2010502822A (en) Polymer stabilized liposome compositions and methods of use
JPH10510260A (en) Controlled release composition forming reverse micelle (L2) structure or normal micelle (L1) structure
Mosquera et al. Incorporation of liposomes containing squid tunic ACE‐inhibitory peptides into fish gelatin
CA2084184A1 (en) Recombinantly produced lipases for therapeutical treatment
JP2002255847A (en) Collagen production promoter, functional food and pharmaceutical preparation
ATE438389T1 (en) MIXING SYSTEM FOR PROVIDING SOLUBILITY OF PHARMACEUTICAL ACTIVE INGREDIENTS IN POLYMER MATRICES
CA2792965A1 (en) Stable aqueous mia/cd-rap formulations
EP2745849A1 (en) Polydeoxyribonucleotides composition and uses thereof
CN111148511A (en) Composition for improving bioavailability of drugs, supplements and ingested substances
WO1999029886A8 (en) Formation of conjugated unsaturated fatty acids
Yeole et al. A review on nanocochleate–A novel lipid based drug delivery system
WO2004004705A3 (en) Pharmaceutical formulations for preparing drink products
EP3655021B1 (en) Adenosine deaminase for treating or ameliorating scleroderma-associated vasculopathy
US20080058249A1 (en) Complexes
CN112040958A (en) Peptide-containing formulations
WO1999043299A3 (en) Oral formulation for hydrophilic drugs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1)EPC(EPO F1205A DATED 230904)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP